摘要

Objectives: This case studies not only has proven there is much more tolerable treatment available in the market particularly for this rare autoimmune condition. Not only it's effective, with no adverse effects reported up to date, and most importantly easy to use and showed favourable response within such a short period of time. With the presence of this treatment, patients would not need to be on topical steroid and cytotoxic chemotherapy based treatments for long period of time which could potentially caused secondary inflammation as steroid induced inflammatory skin reactions. Introduction: Exosomes have gained significant attention in the field of medicine in recent years, and they hold great promise for various applications in cosmetic and medicine. However, the effectiveness in treating severe inflammatory skin conditions in Dermatomyositis has not been reported yet. Materials / method: In this case study, we are looking at the response of one of the rare autoimmune diseases Dermatomyositis towards PSCD (Plant Stem Cells Derived) Exosome as a stand alone treatment for inflammatory skin conditions. Even more interesting given that the patient found to be Positive with Mi-2 Beta antibody on myositis 11 blood panel antibody testing. Which means the risk of developing malignancy almost 5 folds compared to general populations. Results: Therapeutically the patient was treated with topical cream high in exosome concentrated for 6 weeks twice a day despite marked improvement seen in just after 2 weeks. This is to avoid and ensure no relapses. Patient continues to improved over the 6 weeks course and subsequently maintained with preparation with lower exosome concentration. Conclusion: This is the first case demonstrating the effectiveness of topical exosome preparation in treating severe inflammatory skin conditions in a rare autoimmune disease, Dermatomyositis. Exosome based treatment should be considered as 1st line treatment of choice based on results, tolerability and nil side effects reported up top to date compared to existing treatments. Hence, increases compliance and patient's QoL.